Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19
OwnerLawrence LOOMISinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to lateral flow assay devices adapted to detect IgA specific for SARS-CoV-2 in biological samples from subjects suspected to have COVID-19, and methods of using the lateral flow assay devices.
Claims20
A method for the detection of an IgA antibody directed against a component of SARS-CoV-2 virus (COVID-19 virus) selected from the group consisting of Spike protein, RBD, NP, S1, and/or S2, and fragments, truncations, and variants thereof, comprising the steps of:
- i) contacting a biological sample with a colloidal gold labeled anti-human IgA1 and IgA2 antibody to produce a reacted sample;
- and
- ii) contacting the reacted sample with a lateral flow device comprising a SARS-CoV-2 virus capture line comprising one or more viral components selected from the group consisting of Spike protein, RBD, NP, S1, and/or S2, and fragments, truncations, and variants thereof.
2-4. (canceled)
10-14. (canceled)
A lateral flow assay device for the detection of human IgA antibody directed against SARS-CoV-2 viral particles or proteins, including fragments, truncations, or variants of the viral proteins, the lateral flow device comprising:
- an anti-human IgA1 and IgA2 tagged with colloidal gold dried on a pad which is affixed to a membrane of the lateral flow device;
- and
- a capture line on the membrane comprising SARS-CoV-2 viral particles or proteins, including fragments, truncations, or variants of the viral proteins,
- wherein the SARS-CoV-2 viral proteins are selected from the group consisting of Spike protein, RBD, NP, S1, and/or S2.
(canceled)
A method for identifying a subject as having or being an asymptomatic carrier of SARS-CoV-2 comprising:
- i) contacting a biological sample from the subject with a colloidal gold labeled anti-human IgA antibody to produce a reacted sample;
- ii) contacting the reacted sample with a lateral flow device comprising a capture line comprised of SARS-CoV-2 viral particles or SARS-CoV-2 Spike protein, RBD, NP, S1, and/or S2, and fragments, truncations, and variants thereof;
- and
- determining the presence of IgA specific for SARS-CoV-2 based on a visual indication of the reacted sample binding to the capture line.
25-30. (canceled)
Dependencies are inferred from the claim text.